Back to Results
First PageMeta Content
Organic chemistry / Atypical antipsychotics / Organochlorides / Schizophrenia / Alcohols / Clozapine / Antipsychotic / Management of schizophrenia / Typical antipsychotic / Psychiatry / Chemistry / Piperazines


The Journal of Mental Health Policy and Economics J Ment Health Policy Econ 7, Should Clozapine Continue to be Restricted to Third-Line Status for Schizophrenia?: A Decision-Analytic Model
Add to Reading List

Document Date: 2004-05-18 17:05:32

Open Document

File Size: 106,75 KB

Share Result on Facebook

City

Ottawa / Boston / New York / Washington / D.C. / Montvale / Berlin / Hyattsville / Williamstown / /

Company

Eaton / Lehman / Oxford University Press / TreeAge Software / Spiegel / Medical Economics Company / Consumer Price Index / American Psychiatric Press / /

Country

United States / Canada / United Kingdom / /

Currency

USD / /

/

Event

Product Recall / Product Issues / /

Facility

National Institute of Mental Health / Arch Gen Psychiatry / Women’s Hospital / /

/

IndustryTerm

pharmaceutical / pharmaceuticals / health care systems / mental health care systems / generic products / /

MarketIndex

Consumer Price / /

MedicalCondition

treated schizophrenia / JE / ICMPE Psychosis Tardive Dyskinesia / chronic lymphocytic leukemia / severe chronic schizophrenia / Clozapine-induced agranulocytosis / fatal agranulocytosis / neuroleptic-resistant schizophrenia / dyskinesia / severe infection / psychotic disorders / treatment-resistant chronic schizophrenia / drug-induced akathisia / chronic form / exclusively treatment-resistant schizophrenia / chronic schizophrenia / agranulocytosis / refractory schizophrenia / episode schizophrenia / schizophrenic disorders / treatment-resistant schizophrenia / therapy-refractory schizophrenia / cancer / Schizophrenia / Parkinsonism / Recovered From Psychosis Agranulocytosis / Outpatient care Residential treatment TD treatment Agranulocytosis / treatmentresistant schizophrenia / tardive dyskinesia / akathisia / /

MedicalTreatment

chemotherapy / drug therapy / /

NaturalFeature

Halpern MT / Tsuang MT / /

Organization

Harvard Medical School / Women’s Hospital / Canadian Coordinating Office for Health Technology Assessment / Division of Pharmacoepidemiology and Pharmacoeconomics / American Psychiatric Association / Department of Medicine / U.S. Food and Drug Administration / National Center for Health Statistics / Oxford University / Department of Medicine / Brigham and Women / National Institute of Mental Health / /

Person

Beck JR. / However / Philip S. Wang / David A. Ganz / S. WANG ET AL / John Wiley / Heinrich K. Randomized / /

/

Position

Walker / General / costeffectiveness clinical decision analysis model for schizophrenia / Decision-Analytic Model / model / Singer / /

Product

Neuroleptic / Conventional Antipsychotic / Haloperidol / risperidone / olanzapine / Clozapine / Bebbington P. Atypical / Monte Carlo / Costs Medication / Clozaril / /

ProvinceOrState

New Jersey / Maryland / Washington / Massachusetts / /

PublishedMedium

Health Economics / /

RadioStation

Walker AM / /

Technology

chemotherapy / simulation / /

SocialTag